<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Optimi Health Corp. — News on 6ix</title>
<link>https://6ix.com/company/optimi-health-corp</link>
<description>Latest news and press releases for Optimi Health Corp. on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Thu, 23 Apr 2026 11:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/optimi-health-corp" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo683683d278dffbe2df1696f2.webp</url>
<title>Optimi Health Corp.</title>
<link>https://6ix.com/company/optimi-health-corp</link>
</image>
<item>
<title>Optimi Health Files LIFE Offering Document in Connection with NASDAQ Listing</title>
<link>https://6ix.com/company/optimi-health-corp/news/optimi-health-files-life-offering-document-in-connection-with-nasdaq-listing</link>
<guid isPermaLink="true">https://6ix.com/company/optimi-health-corp/news/optimi-health-files-life-offering-document-in-connection-with-nasdaq-listing</guid>
<pubDate>Thu, 23 Apr 2026 11:00:00 GMT</pubDate>
<description>Vancouver, British Columbia--(Newsfile Corp. - April 23, 2026) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) (the "Company" or "Optimi"), a commercial-stage pharmaceutical manufacturer of regulated psychedelic drug products, today announced that further to its press release dated March 16, 2026, it intends to complete a portion of its previously announced offering of common shares (the "Offering") in Canada pursuant to the Listed Issuer Financing Exemption contained in Part A of...</description>
</item>
<item>
<title>Optimi Health Launches Ibogaine Initiative as U.S. Executive Order Signals Pathway for Psychedelic Drug Products</title>
<link>https://6ix.com/company/optimi-health-corp/news/optimi-health-launches-ibogaine-initiative-as-us-executive-order-signals-pathway-for-psychedelic-drug-products</link>
<guid isPermaLink="true">https://6ix.com/company/optimi-health-corp/news/optimi-health-launches-ibogaine-initiative-as-us-executive-order-signals-pathway-for-psychedelic-drug-products</guid>
<pubDate>Mon, 20 Apr 2026 10:00:00 GMT</pubDate>
<description>The Company's Health Canada-licensed GMP psychedelic manufacturing platform ready to serve emerging demand for ibogaine, a naturally occurring alkaloid under investigation for opioid use disorder, PTSD, and traumatic brain injuryVancouver, British Columbia--(Newsfile Corp. - April 20, 2026) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) (the "Company" or "Optimi"), a commercial-stage pharmaceutical manufacturer of regulated psychedelic drug products, today launched its Ibogaine...</description>
</item>
<item>
<title>Optimi Health Announces Proposed Nasdaq Listing and U.S. Underwritten Public Offering</title>
<link>https://6ix.com/company/optimi-health-corp/news/optimi-health-announces-proposed-nasdaq-listing-and-us-underwritten-public-offering</link>
<guid isPermaLink="true">https://6ix.com/company/optimi-health-corp/news/optimi-health-announces-proposed-nasdaq-listing-and-us-underwritten-public-offering</guid>
<pubDate>Mon, 16 Mar 2026 11:00:00 GMT</pubDate>
<description>Vancouver, British Columbia--(Newsfile Corp. - March 16, 2026) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) (the "Company" or "Optimi"), a commercial-stage pharmaceutical company focused on manufacturing and distributing finished psychedelic drug products, today announced that it has commenced an underwritten public offering in the United States (the "Offering") of its common shares, no par value (the "Shares"), pursuant to a registration statement filed with the United States...</description>
</item>
<item>
<title>Optimi Health Reports Early Clinical Rollout of Natural Psilocybin Capsules for Treatment-Resistant Depression in Australia</title>
<link>https://6ix.com/company/optimi-health-corp/news/optimi-health-reports-early-clinical-rollout-of-natural-psilocybin-capsules-for-treatment-resistant-depression-in-australia</link>
<guid isPermaLink="true">https://6ix.com/company/optimi-health-corp/news/optimi-health-reports-early-clinical-rollout-of-natural-psilocybin-capsules-for-treatment-resistant-depression-in-australia</guid>
<pubDate>Thu, 26 Feb 2026 12:00:00 GMT</pubDate>
<description>First Patients of 2026 Treated Outside of Sponsor-Led Clinical Trials Under Australia's Regulated FrameworkVancouver, British Columbia--(Newsfile Corp. - February 26, 2026) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a Health Canada-licensed manufacturer of pharmaceutical-grade psychedelic drug products, today reported that patients diagnosed with treatment-resistant depression (TRD) have now been treated in Australia using the Company's naturally...</description>
</item>
<item>
<title>Optimi Health Completes Psilocybin Export to Australia for Treatment Resistant Depression</title>
<link>https://6ix.com/company/optimi-health-corp/news/optimi-health-completes-psilocybin-export-to-australia-for-treatment-resistant-depression</link>
<guid isPermaLink="true">https://6ix.com/company/optimi-health-corp/news/optimi-health-completes-psilocybin-export-to-australia-for-treatment-resistant-depression</guid>
<pubDate>Thu, 19 Feb 2026 07:00:00 GMT</pubDate>
<description>Naturally-Derived 5 mg Psilocybin Capsules Mark the Company's Second Drug in Market Under Australia's Authorised Prescriber SchemeVancouver, British Columbia--(Newsfile Corp. - February 19, 2026) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a Health Canada-licensed manufacturer of pharmaceutical-grade psychedelic drug products, today announced the export of its GMP-manufactured natural 5 mg psilocybin capsules to Australia for the treatment of patients</description>
</item>
<item>
<title>Optimi Health Reports First MDMA-Assisted Treatments of 2026 are Underway Across an Expanded Network of Australian Clinics</title>
<link>https://6ix.com/company/optimi-health-corp/news/optimi-health-reports-first-mdma-assisted-treatments-of-2026-are-underway-across-an-expanded-network-of-australian-clinics</link>
<guid isPermaLink="true">https://6ix.com/company/optimi-health-corp/news/optimi-health-reports-first-mdma-assisted-treatments-of-2026-are-underway-across-an-expanded-network-of-australian-clinics</guid>
<pubDate>Tue, 17 Feb 2026 12:00:00 GMT</pubDate>
<description>MDMA-assisted therapy for PTSD delivered through Optimi's direct-to-clinic supply model under Australia's Authorised Prescriber SchemeVancouver, British Columbia--(Newsfile Corp. - February 17, 2026) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a Health Canada-licensed manufacturer of pharmaceutical psychedelic drug products, today reported that the first patients of 2026 have been treated using the Company's MDMA capsules at authorised clinics across.</description>
</item>
<item>
<title>Optimi Health Completes MDMA Export for PTSD Treatment Under Australia's Authorised Prescriber Scheme</title>
<link>https://6ix.com/company/optimi-health-corp/news/optimi-health-completes-mdma-export-120000701</link>
<guid isPermaLink="true">https://6ix.com/company/optimi-health-corp/news/optimi-health-completes-mdma-export-120000701</guid>
<pubDate>Mon, 09 Feb 2026 12:00:00 GMT</pubDate>
<description>Vancouver, British Columbia--(Newsfile Corp. - February 9, 2026) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a Health Canada-licensed manufacturer of pharmaceutical psychedelic drug products, today reported that it has completed its first export of MDMA capsules to Australia in 2026 under the Authorised Prescriber Scheme.The export included 1,000 of Optimi's MDMA capsules in a standardised 60 mg dosage form, supplied for use in authorised clinical...</description>
</item>
<item>
<title>Optimi Health Completes First 2026 Production of MDMA and Psilocybin Capsules</title>
<link>https://6ix.com/company/optimi-health-corp/news/optimi-health-completes-first-2026-120000640</link>
<guid isPermaLink="true">https://6ix.com/company/optimi-health-corp/news/optimi-health-completes-first-2026-120000640</guid>
<pubDate>Mon, 26 Jan 2026 12:00:00 GMT</pubDate>
<description>Australia's Department of Health has issued import permits for Optimi's MDMA and psilocybin capsules for use under the Authorised Prescriber SchemeVancouver, British Columbia--(Newsfile Corp. - January 26, 2026) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a Health Canada-licensed manufacturer of pharmaceutical psychedelic drug products, today reported that it has completed a production cycle for its MDMA and psilocybin capsules intended for supply...</description>
</item>
<item>
<title>Early Warning Press Release in Accordance with National Instrument 62-103</title>
<link>https://6ix.com/company/optimi-health-corp/news/early-warning-press-release-in-accordance-with-national-instrument-62-103-4</link>
<guid isPermaLink="true">https://6ix.com/company/optimi-health-corp/news/early-warning-press-release-in-accordance-with-national-instrument-62-103-4</guid>
<pubDate>Wed, 21 Jan 2026 22:00:00 GMT</pubDate>
<description>Vancouver, British Columbia--(Newsfile Corp. - January 21, 2026) - Cathay Visions Enterprises Ltd. (the "Acquiror") acquired 102,500 common shares (each a "Common Share") of Optimi Health Corp. (the "Issuer") at a price of $0.32 in the public market. Prior to giving effect to the foregoing acquisition of Common Shares, the Acquiror owned and/or had control over an aggregate of 12,583,938 Common Shares, representing approximately 13.02% of the issued and outstanding Common Shares of the Issuer on</description>
</item>
<item>
<title>Optimi Health Announces Equity Incentive Grants and Corporate Update</title>
<link>https://6ix.com/company/optimi-health-corp/news/optimi-health-announces-equity-incentive-120000602</link>
<guid isPermaLink="true">https://6ix.com/company/optimi-health-corp/news/optimi-health-announces-equity-incentive-120000602</guid>
<pubDate>Fri, 16 Jan 2026 12:00:00 GMT</pubDate>
<description>Vancouver, British Columbia--(Newsfile Corp. - January 16, 2026) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a Canadian GMP-compliant manufacturer of MDMA and psilocybin, today announced a series of equity compensation and marketing initiatives designed to support its growth strategy and enhance market awareness.Equity Incentive GrantsOptimi announces that, pursuant to its equity incentive plan and subject to acceptance by the Canadian Securities...</description>
</item>
<item>
<title>Optimi Health to Present at the Sidoti Micro-Cap Conference on January 21-22, 2026</title>
<link>https://6ix.com/company/optimi-health-corp/news/optimi-health-present-sidoti-micro-123000019</link>
<guid isPermaLink="true">https://6ix.com/company/optimi-health-corp/news/optimi-health-present-sidoti-micro-123000019</guid>
<pubDate>Wed, 14 Jan 2026 12:30:00 GMT</pubDate>
<description>Vancouver, British Columbia--(Newsfile Corp. - January 14, 2026) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a leading producer of prescribed psychedelic treatments for mental health therapies, today announced that management has been invited to present at the Sidoti Micro-Cap Virtual Conference on January 21-22, 2026.Chief Executive Officer Dane Stevens is scheduled to host virtual one-on-one meetings with institutional investors throughout the event</description>
</item>
<item>
<title>Optimi Health Announces Appointment of New Director</title>
<link>https://6ix.com/company/optimi-health-corp/news/optimi-health-announces-appointment-director-120000853</link>
<guid isPermaLink="true">https://6ix.com/company/optimi-health-corp/news/optimi-health-announces-appointment-director-120000853</guid>
<pubDate>Thu, 18 Dec 2025 12:00:00 GMT</pubDate>
<description>Vancouver, British Columbia--(Newsfile Corp. - December 18, 2025) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a Canadian GMP-compliant manufacturer of MDMA and psilocybin, is pleased to announce the appointment of Mr. Jason Mosberian as a director of the Company, effective immediately (the "Appointment"). Mr. Mosberian graduated from the Sauder School of Business and earned his CPA designation in 2011 working in audit in public practice for 6 years...</description>
</item>
<item>
<title>Optimi Health to Supply MDMA to MAPS Israel's Clinical Trial for Trauma-Related PTSD</title>
<link>https://6ix.com/company/optimi-health-corp/news/optimi-health-supply-mdma-maps-120000217</link>
<guid isPermaLink="true">https://6ix.com/company/optimi-health-corp/news/optimi-health-supply-mdma-maps-120000217</guid>
<pubDate>Wed, 26 Nov 2025 12:00:00 GMT</pubDate>
<description>Approved multicenter study sponsored by Sheba Medical Center to compare group and individual MDMA-assisted therapy for 168 patients experiencing trauma-related PTSDVancouver, British Columbia--(Newsfile Corp. - November 26, 2025) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a Canadian manufacturer of pharmaceutical-grade psychedelics, including MDMA and naturally derived psilocybin, has been selected to supply the MDMA capsules for MAPS Israel's...</description>
</item>
<item>
<title>Optimi Health Provides Corporate Update</title>
<link>https://6ix.com/company/optimi-health-corp/news/optimi-health-provides-corporate-110000620</link>
<guid isPermaLink="true">https://6ix.com/company/optimi-health-corp/news/optimi-health-provides-corporate-110000620</guid>
<pubDate>Tue, 21 Oct 2025 11:00:00 GMT</pubDate>
<description>Vancouver, British Columbia--(Newsfile Corp. - October 21, 2025) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a Canadian manufacturer of pharmaceutical psychedelics including MDMA and naturally-derived psilocybin, is pleased to announce that it has passed its Drug Establishment Licence (DEL) inspection by Health Canada, with no critical observations, resulting in a GMP-compliant rating for the fabrication and distribution of pharmaceutical-grade...</description>
</item>
<item>
<title>Optimi Health's Psilocybin Capsules Selected for Medibank Insurance Program</title>
<link>https://6ix.com/company/optimi-health-corp/news/optimi-healths-psilocybin-capsules-selected-110000652</link>
<guid isPermaLink="true">https://6ix.com/company/optimi-health-corp/news/optimi-healths-psilocybin-capsules-selected-110000652</guid>
<pubDate>Mon, 06 Oct 2025 11:00:00 GMT</pubDate>
<description>Australia's largest private health insurer expands its AUD $10M psychotherapy program to cover psilocybin for Treatment-Resistant Depression, building on earlier MDMA coverage for PTSDVancouver, British Columbia--(Newsfile Corp. - October 6, 2025) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a Canadian GMP-compliant manufacturer of MDMA and psilocybin, today announced that its 5mg naturally-derived psilocybin capsules have been selected for inclusion..</description>
</item>
<item>
<title>Optimi Announces Public Filing of Registration Statement for Proposed U.S. Initial Public Offering</title>
<link>https://6ix.com/company/optimi-health-corp/news/optimi-announces-public-filing-registration-110000594</link>
<guid isPermaLink="true">https://6ix.com/company/optimi-health-corp/news/optimi-announces-public-filing-registration-110000594</guid>
<pubDate>Mon, 08 Sep 2025 11:00:00 GMT</pubDate>
<description>Vancouver, British Columbia--(Newsfile Corp. - September 8, 2025) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company") a Canadian drug manufacturer of MDMA and naturally-derived psilocybin announces that it has publicly filed a registration statement with the U.S. Securities and Exchange Commission (the "SEC") relating to a proposed initial public offering of its common shares in the United States.The number of common shares to be sold and the price range for..</description>
</item>
<item>
<title>Optimi Health Announces Launch of Psilocybin Capsules in Australia for Treatment-Resistant Depression</title>
<link>https://6ix.com/company/optimi-health-corp/news/optimi-health-announces-launch-psilocybin-113000114</link>
<guid isPermaLink="true">https://6ix.com/company/optimi-health-corp/news/optimi-health-announces-launch-psilocybin-113000114</guid>
<pubDate>Wed, 03 Sep 2025 11:30:00 GMT</pubDate>
<description>Export of 1,000 natural psilocybin capsules for prescription use under Australia's Authorised Prescriber Scheme follows the Company's successful launch of MDMA sales in 2024Vancouver, British Columbia--(Newsfile Corp. - September 3, 2025) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a Canadian manufacturer of GMP psychedelic medicines, is pleased to announce the commercial launch of its natural psilocybin capsules in Australia, which are now being...</description>
</item>
<item>
<title>Optimi Health Announces $3.45 Million Convertible Financing and Extension of Secured Term Loan</title>
<link>https://6ix.com/company/optimi-health-corp/news/optimi-health-announces-3-45-110000684</link>
<guid isPermaLink="true">https://6ix.com/company/optimi-health-corp/news/optimi-health-announces-3-45-110000684</guid>
<pubDate>Fri, 18 Jul 2025 11:00:00 GMT</pubDate>
<description>Vancouver, British Columbia--(Newsfile Corp. - July 18, 2025) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a Canadian drug manufacturer and formulator of GMP-grade MDMA and natural psilocybin, is pleased to announce that it has entered into subscription agreements pursuant to which it proposes to complete a non-brokered private placement (the "Offering") with two non-arm's length parties (each an "Investor") of 3,450 unsecured convertible debentures of</description>
</item>
<item>
<title>Optimi Health Completes Largest-to-Date MDMA Export to Australia for PTSD Therapy</title>
<link>https://6ix.com/company/optimi-health-corp/news/optimi-health-completes-largest-date-110000859</link>
<guid isPermaLink="true">https://6ix.com/company/optimi-health-corp/news/optimi-health-completes-largest-date-110000859</guid>
<pubDate>Thu, 08 May 2025 11:00:00 GMT</pubDate>
<description>1,000 GMP doses of MDMA now reaching patients with PTSD under Australia's Authorised Prescriber Scheme; Department of Veterans' Affairs to fund treatment for veterans Vancouver, British Columbia--(Newsfile Corp. - May 8, 2025) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a Canadian drug manufacturer and formulator of GMP-grade MDMA and natural psilocybin, has completed its largest international export to date of MDMA capsules to Australia, supporting t</description>
</item>
<item>
<title>Optimi Health Obtains U.S. FDA Drug Establishment Registration</title>
<link>https://6ix.com/company/optimi-health-corp/news/optimi-health-obtains-u-fda-113500706</link>
<guid isPermaLink="true">https://6ix.com/company/optimi-health-corp/news/optimi-health-obtains-u-fda-113500706</guid>
<pubDate>Mon, 05 May 2025 11:35:00 GMT</pubDate>
<description>The Company is now recognized by the U.S. FDA to support the cross-border supply of GMP MDMA and psilocybin to authorized entities in the United States. Vancouver, British Columbia--(Newsfile Corp. - May 5, 2025) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a manufacturer of GMP-certified MDMA and psilocybin, has received its U.S. FDA Establishment Identifier (FEI) number—a key regulatory step for engaging in FDA filings and compliant supply ...</description>
</item>
</channel>
</rss>